Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;39(5):218-223.
doi: 10.1177/87551225231196047. Epub 2023 Sep 2.

Impact of a Standardized, Pharmacist-Initiated "Test-Claim" Workflow for Anticipating Barriers to Accessing Discharge Antimicrobials

Affiliations

Impact of a Standardized, Pharmacist-Initiated "Test-Claim" Workflow for Anticipating Barriers to Accessing Discharge Antimicrobials

Surafel G Mulugeta et al. J Pharm Technol. 2023 Oct.

Abstract

Background: Inability to access and afford discharge oral antimicrobials may delay discharges or result in therapeutic failure. "Test-claims" have the potential to identify such barriers. Objective: This study evaluated discharge antimicrobial access and patient outcomes after implementation of a standardized, inpatient pharmacist-initiated antimicrobial discharge medication cost inquiry (aDMCI) process. Methods: This was an Institutional Review Board (IRB)-approved, pilot retrospective cohort study that included adults admitted for ≥72 hours from November 1, 2018, to February 28, 2019, and discharged on oral antimicrobials. Patients with a cost inquiry (aDMCI group) were compared with those without (standard-of-care, SOC, group). Primary endpoint was discharge delay. Secondary endpoints included percentage of patients discharged on suboptimal antimicrobials and medication errors from aDMCI. Results: 84 patients were included: 43 in SOC and 41 in aDMCI. Seventy-five antimicrobial cost inquiries were evaluated among 41 patients. There were no discharge delays or medication errors associated with the standardized "test-claim" (aDMCI) workflow. Patients in the SOC group had a greater Charlson Comorbidity Index (4 [2-6] vs 2 [1-4], P =0.004), were more likely to be immunosuppressed (24, 56% vs 12, 29%; P =0.014), and had longer hospitalization (8 [5-15] vs 6 [5-9] days, P =0.026). Primary access barriers were prior-authorization (8, 11%) and associated with linezolid and moxifloxacin cost inquiries. Most aDMCIs results were available in <24 hours (66, 88%). Conclusions: The aDMCI process is safe and offers an actionable transition of care tool that can identify barriers to accessing discharge medications while insulating patients from surprise out-of-pocket cost.

Keywords: antimicrobials; discharge planning; test-claims; transition of care.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Antimicrobial discharge medication cost inquiry (n = 75) pattern.

References

    1. Farris B, Shakowski C, Mueller SW, Phong S, Kiser TH, Jacknin G. Patient nonadherence to filling discharge medication prescriptions from the emergency department: barriers and clinical implications. Am J Health Syst Pharm. 2018;75(5):316-320. doi:10.2146/ajhp170198 - DOI - PubMed
    1. Viswanathan M, Golin CE, Jones CD, et al.. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med. 2012;157(11):785–795. doi:10.7326/0003-4819-157-11-201212040-00538 - DOI - PubMed
    1. Cutler T, She Y, Barca J, et al.. Impact of pharmacy intervention on prior authorization success and efficiency at a university medical center. J Manag Care Spec Pharm. 2016;22(10):1167-1171. doi:10.18553/jmcp.2016.22.10.1167 - DOI - PMC - PubMed
    1. Bunnell KL, Danziger LH, Johnson S. Economic barriers in the treatment of clostridium difficile infection with oral vancomycin. Open Forum Infect Dis. 2017;4(2):ofx078. doi:10.1093/ofid/ofx078 - DOI - PMC - PubMed
    1. Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):e016982. doi:10.1136/bmjopen-2017-016982 - DOI - PMC - PubMed

LinkOut - more resources